(Q46434533)

22 December 2017

title

Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists? (English)

1 reference

22 December 2017

1 reference

1

1 reference

22 December 2017

publication date

12 August 2008

1 reference

22 December 2017

Nature Clinical Practice Cardiovascular Medicine

published in

1 reference

22 December 2017

volume

5

1 reference

22 December 2017

issue

10

1 reference

22 December 2017

page(s)

610-612

1 reference

22 December 2017

Metabolic obesity: the paradox between visceral and subcutaneous fat.

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1319

Abdominal obesity and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1319

7 January 2021

The link between abdominal obesity, metabolic syndrome and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1319

7 January 2021

Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1319

7 January 2021

The endocannabinoid system in obesity and type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1319

7 January 2021

Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1319

7 January 2021

The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1319

7 January 2021

Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1319

7 January 2021

Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1319

7 January 2021

Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: efficacy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1319

7 January 2021

Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1319

7 January 2021

Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1319

7 January 2021

Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1319

7 January 2021

Targeting the endocannabinoid system: to enhance or reduce?

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1319

7 January 2021

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1319

7 January 2021

Identifiers

DOI

10.1038/NCPCARDIO1319

1 reference

22 December 2017

1 reference

22 December 2017